ニュース

Investing.com3 日
# FDAがNuvation Bioの肺がん治療薬タレトレクチニブを承認
ニューヨーク - 米国食品医薬品局（FDA）は水曜日、Nuvation Bio Inc.（NYSE: NUVB）のIBTROZI（タレトレクチニブ）を成人の局所進行性または転移性ROS1陽性非小細胞肺がん（NSCLC）患者向けに承認したと同社が発表した。この発表は、現在時価総額8億600万ドル、株価2. ...
Pharmabiz21 時間
US FDA approves Nuvation Bio’s taletrectinib for treatment of advanced ROS1-positive non ...
US FDA approves Nuvation Bio’s taletrectinib for treatment of advanced ROS1-positive non-small cell lung cancer: New York Saturday, June 14, 2025, 14:00 Hrs [IST] Nuvation Bio I ...
PMLive2 日
FDA approves Nuvation Bio’s TKI inhibitor Ibtrozi to treat rare form of lung cancer
The US Food and Drug Administration (FDA) has approved Nuvation Bio’s Ibtrozi (taletrectinib) to treat adults with a rare and ...
pharmaphorum2 日
FDA clears Nuvation's first product Ibtrozi, for lung cancer
Nuvation Bio is set to launch its first commercial product after the FDA approved its ROS1 inhibitor Ibtrozi as a treatment ...
The Pharma Letter2 日
FDA approves Nuvation Bio’s Ibtrozi for ROS1-positive NSCLC
The US Food and Drug Administration (FDA) yesterday approved Nuvation Bio’s (NYSE: NUVB) Ibtrozi (taletrectinib), a kinase ...
Nuvation Bio: Judgement Day Grows Closer
Read the latest analysis on Nuvation Bio stock. Solid financials, positive analyst sentiment, and insider buying support ...
Nuvation Bio granted FDA approval for lung cancer therapy Ibtrozi
Nuvation Bio (NYSE:NUVB) announced on Wednesday that the U.S. Food and Drug Administration (FDA) has approved its oral ...
BioSpace3 日
Nuvation Scores First FDA Nod With Oral Lung Cancer Drug
Nuvation Bio’s first approved product is Ibtrozi, a CNS-active ROS1 inhibitor that in pivotal studies showed high rates of treatment response in patients with non-small cell lung cancer. The FDA ...